CAJ | 학술논문

目的：比较阿克他利和甲氨蝶呤对类风湿关节炎（RA）的疗效和安全性。方法：120例RA病人随机分为2组，阿克他利组80例，口服阿克他利100 mg， tid×12 wk。甲氨蝶呤组40例，口服甲氨蝶呤10 mg, qw ×12 wk。结果：阿克他利组总有效率为73 %，甲氨蝶呤组为78 %（P>0.05）。不良反应发生率分别为9 % 和18 %，差异有显著意义(P<0.05) 。结论:阿克他利治疗类风湿关节炎的疗效与甲氨蝶呤相似,但在安全性方面明显优于甲氨蝶呤。
목적：비교아극타리화갑안접령대류풍습관절염（RA）적료효화안전성。방법：120례RA병인수궤분위2조，아극타리조80례，구복아극타리100 mg， tid×12 wk。갑안접령조40례，구복갑안접령10 mg, qw ×12 wk。결과：아극타리조총유효솔위73 %，갑안접령조위78 %（P>0.05）。불량반응발생솔분별위9 % 화18 %，차이유현저의의(P<0.05) 。결론:아극타리치료류풍습관절염적료효여갑안접령상사,단재안전성방면명현우우갑안접령。
AIM: To campare the therapeutic effects and security between actarit (MS 932) and methotrexate(MTX) in the treatment of rheumatoid arthritis(RA). 　METHODS: One hundred and twenty patients with RA were randomly divided into two groups. Eighty patients of actarit group receved actarit, 100 mg, po, tid for 12 wk. The other forty patients received methotrexate 10 mg, po, qw for 12 wk as control.　RESULTS: The total effective rates were 73 % for actarit and 78 % for MTX (P>0.05). The adverse reactions were 9 % and 18 %(P<0.05).　CONCLUSION: Actarit is as same as methotrexate in the therapeutic effect, but actarit is better than MTX in security.